Immune Design Receives Orphan Drug Designation for G100 Intratumoral Product Candidate
Feb 22, 2017 13:00 pm UTC| Business
SEATTLE and SOUTH SAN FRANCISCO, Calif., Feb. 22, 2017 -- Immune Design (Nasdaq:IMDZ), a clinical-stage immunotherapy company focused on oncology, today announced that the U.S. Food and Drug Administration (FDA) has...
Ekso Bionics to Present at the Cowen and Company Health Care Conference
Feb 22, 2017 13:00 pm UTC| Business
RICHMOND, Calif., Feb. 22, 2017 -- Ekso Bionics Holdings, Inc. (NASDAQ:EKSO), a robotic exoskeleton company, today announced the company plans to participate in the Cowen and Company Health Care Conference in Boston. ...
Feb 22, 2017 13:00 pm UTC| Business
NEW YORK, Feb. 22, 2017 -- Intra-Cellular Therapies, Inc. (Nasdaq:ITCI), a biopharmaceutical company focused on the development of therapeutics for central nervous system (CNS) disorders, today announced that it will...
Feb 22, 2017 12:40 pm UTC| Business
PLANTATION, Fla., Feb. 22, 2017 -- TradeStation, a Monex Group company and award-winning* online broker-dealer and futures commission merchant, announced today that it topped all other online brokerage firms in five...
PARC Showcases Seven Energy Breakthroughs at ARPA-E Energy Innovation Summit
Feb 22, 2017 12:37 pm UTC| Business
Washington DC, Feb. 22, 2017 -- ARPA-EEnergy Innovation Summit:PARC, a Xerox company, today announced its presence at the U.S. Department of Energy’s Advanced Research Projects Agency-Energy (ARPA-E) Innovation Summitto...
Repligen Reports Fourth Quarter 2016 Financial Results, Provides Guidance for 2017
Feb 22, 2017 12:30 pm UTC| Business
Fourth quarter 2016 revenue of $25.6 million reflects 19% growthFull year 2016 revenue of $104.5 reflects 25% growthFull year 2016 GAAP and adjusted operating income grew 16% and 20% respectively WALTHAM, Mass., Feb. ...
Spark Therapeutics Reports 2016 Financial Results and Business Highlights
Feb 22, 2017 12:30 pm UTC| Business
Investigational voretigene neparvovec Biologics License Application (BLA) on track for completion in early 2017 Three additional clinical-stage programs continue to advance, including initiation of hemophilia A Phase 1/2...